Economic implications of cardiovascular disease management programs: Moving beyond one-off experiments

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 4, 2015, Pages 657-666

  Maru, Shoko ^a   Byrnes, Joshua ^a   Carrington, Melinda J ^b   Stewart, Simon ^b   Scuffham, Paul A ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

Cardiovascular disease; Cost effectiveness; Disease management; Economic evaluation; Heart failure

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; ECONOMIC ASPECT; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; ISCHEMIC HEART DISEASE; NEW YORK HEART ASSOCIATION CLASS; PREVALENCE; QUALITY OF LIFE; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; ECONOMICS; MANAGEMENT; OUTCOME ASSESSMENT; RESEARCH; STANDARDS;

CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); POLICY MAKING; RESEARCH REPORT;

EID: 84945922524     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1046842     Document Type: Article

References (62)

1. What is Cardiovascular disease?. Australian government department of health. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/chronic-cardio [Last accessed 14 May 2014]
2. Johnson A. Measuring DM's net effect is harder than you might think. Managed care 2003; 12:28-32
3. Mark DB, Hlatky MA Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part II. Circulation 2002; 106:626-30
4. Mohler R, Bartoszek G, Meyer G. Quality of reporting of complex healthcare interventions and applicability of the CReDECI list - a survey of publications indexed in PubMed. BMC Med Res Methodol 2013; 13:125
5. Maru S, Byrnes J, Carrington M.J., et al. Systematic review of trial-based analyses reporting the economic impact of heart failure management programs compared with usual care. Eur J Cardiovasc Nurs 2014. [Epub ahead of print]
6. Maru S, Byrnes J, Whitty J.A., et al. Systematic review of model-based analyses reporting the cost-effectiveness and cost-utility of cardiovascular disease management programs. Eur J Cardiovasc Nurs 2015; 14:26-33
7. Feltner C, Jones CD, Cene C.W., et al. Transitional Care Interventions to Prevent Readmissions for Persons With Heart Failure. A Systematic Review and Meta-analysisTransitional Care for Persons With Heart Failure. Ann Intern Med 2014; 160:774-84
8. Angermann CE, Störk S, Gelbrich G., et al. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: the interdisciplinary network for heart failure (INH) study. Circulation Heart Failure 2012; 5:25-35
9. Gillespie P, O'Shea E, Murphy AW, et al The cost-effectiveness of the SPHERE intervention for the secondary prevention of coronary heart disease. Int J Technol Assess Health Care 2010; 26:263-71
10. Gillespie P, O'Shea E, Murphy AW, et al Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease. Eur J Health Econ 2012; 13:429-43
11. Riegel B, Lee CS, Sochalski J. Developing an Instrument to Measure Heart Failure Disease Management Program Intensity and Complexity. Circulation 2010; 3:324-30
12. Del Sindaco D., Pulignano G, Minardi G., et al. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure. J Cardiovasc Med (Hagerstown) 2007; 8:324-9
13. Pulignano G, Del Sindaco D, Di Lenarda A, et al. Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a cost-effectiveness, pilot study. J Cardiovasc Med (Hagerstown) 2010; 11:739-47
14. Galbreath AD, Krasuski RA, Smith B, et al Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. Circulation 2004; 110:3518-26
15. Smith B, Hughes-Cromwick PF, Forkner E., et al. Cost-effectiveness of telephonic disease management in heart failure. Am J Manag Care 2008; 14:106-15
16. Miller G, Randolph S, Forkner E., et al. Long-term cost-effectiveness of disease management in systolic heart failure. Med Decis Making 2009; 29:325-33
17. Campbell and Cochrane Economics Methods Group and the Evidence for Policy and Practice Information and Coordinating Centre. 'CCEMG - EPPI-Centre Cost Converter'. Available from: http://eppi.ioe.ac.uk/costconversion/default.aspx [Last accessed 4 November 2014]
18. D'Agostino R.B., Russell MW, Huse D.M., et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139:272-81
19. Satagopan JM, Ben-Porat L, Berwick M., et al. A note on competing risks in survival data analysis. Br J Cancer 2004; 91:1229-35
20. Gooley TA, Leisenring W, Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18:695-706
21. Krumholz HM, Weintraub WS, Bradford W.D., et al. Task force #2-the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference. J Am Coll Cardiol 2002; 40: 603-15
22. Dunagan WC, Littenberg B, Ewald G.A., et al. Randomized trial of a nurse-administered, telephone-based disease management program for patients with heart failure. J Card Fail 2005; 11:358-65
23. Kasper EK, Gerstenblith G, Hefter G., et al. A randomized trial of the efficacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. J Am Coll Cardiol 2002; 39: 471-80
24. Michalsen A, Konig G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998; 80:437-41
25. Braunstein JB, Anderson GF, Gerstenblith G, et al Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42:1226-33
26. Culler SD, Parchman ML, Przybylski M. Factors Related to Potentially Preventable Hospitalizations Among the Elderly. Med Care 1998; 36:804-17
27. Maslow K, Ouslander JG Measurement of potentially preventable hospitalizations (a white paper); The Long-term Quality Alliance. Available from: www.ltqa.org/2012-02-16-ltqa-white-paper-offers-guidance-for-long-term-care-organizations-to-measure-preventable-hospitalizations.html [Last accessed 10 November 2014]
28. Goldfield NI, McCullough EC, Hughes J.S., et al. Identifying potentially preventable readmissions. Health Care Financ Rev 2008; 30:75-91
29. Atienza F, Anguita M, Martinez-Alzamora N, et al. Multicenter randomized trial of a comprehensive hospital discharge and outpatient heart failure management program. Eur J Heart Fail 2004; 6:643-52
30. Stewart S, Pearson S, Horowitz JD Effects of a home-based intervention among patients with congestive heart failure discharged from acute hospital care. Arch Intern Med 1998; 158:1067-72
31. Stewart S, Marley JE, Horowitz JD Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 1999; 354:1077-83
32. Neumann PJ, Cohen JT Cost savings and cost-effectiveness of clinical preventive care. Syn Project Res Syn Report 2009(18): 48508
33. Gandjour A, Lauterbach KW Does prevention save costs? Considering deferral of the expensive last year of life. J Health Econ 2005; 24:715-24
34. Conklin A, Nolte E. Disease management evaluation (A comprehensive review of current state of the art). RAND Corp 2010
35. Nolte E, Annalijn C, John L., et al. Evaluating chronic disease management: Recommendations for funders and users. RAND Corporation, Santa Monica, CA; 2012. Available from: http://www.rand.org/pubs/technical-reports/TR1213
36. Murray MD, Young J, Hoke S., et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med 2007; 146:714-25
37. Lopez Cabezas C., Falces Salvador C, Cubi Quadrada D, et al. Randomized clinical trial of a postdischarge pharmaceutical care program vs regular follow-up in patients with heart failure. Farm 2006; 30:328-42
38. Yu J, Shah BM, Ip E.J., et al. A Markov model of the cost-effectiveness of pharmacist care for diabetes in prevention of cardiovascular diseases: evidence from Kaiser Permanente Northern California. J Manag Care Pharm 2013; 19:102-14
39. A Dictionary of Epidemiology, Third Edition; Edited by John M. Last 1995
40. Casteels M, Flamion B. Open-label trials and drug registration: a European regulator's view. J Thromb Haemost 2008; 6:232-4
41. Beyer-Westendorf J., Buller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different? J Thromb Haemost 2011; 9:2153-8
42. Nolte E, Conklin A, Adams J.L., et al. Evaluating chronic disease management. RAND Corporation 2012
43. Murphy AW, Cupples ME, Smith S.M., et al. Effect of tailored practice and patient care plans on secondary prevention of heart disease in general practice: cluster randomised controlled trial. BMJ 2009; 339: b4220
44. Jafar TH, Islam M, Bux R., et al. Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation 2011; 124:1615-25
45. Shiell A, Hawe P, Gold L. Complex interventions or complex systems? Implications for health economic evaluation. BMJ 2008; 336:1281-3
46. Pawson R, Greenhalgh T, Harvey G., et al. Realist review-a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy 2005; 10(suppl 1):21-34
47. Clark AM, Briffa TG, Thirsk L, et al What football teaches us about researching complex health interventions. BMJ 2012; 345:e8316
48. Clark AM. What are the components of complex interventions in healthcare? Theorizing approaches to parts, powers and the whole intervention. Soc Sci Med 2013; 93:185-93
49. Glouberman S, Zimmermann B. Complicated and complex systems: what would successful reform of medicare look like? Commission on the Future of Health Care in Canada. Available from: http://www.alnap.org/resource/8119 [Last accessed 1 March 2015]
50. Reed SD, Li Y, Kamble S., et al. Introduction of the tools for economic analysis of patient management interventions in heart failure costing tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions. Circ Cardiovasc Qual Outcomes 2012; 5:113-19
51. Graves N, Walker D, Raine R., et al. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods. Health Econ 2002; 11: 735-9
52. Briggs A, Claxton K, Sculpher M., et al. Decision modelling for health economic evaluation. Oxford University Press; 2006
53. Briggs AH, O'Brien BJ. The death of cost-minimization analysis? Health Econ 2001; 10:179-84
54. Johnston K, Gray A, Moher M., et al. Reporting the cost-effectiveness of interventions with nonsignificant effect differences: example from a trial of secondary prevention of coronary heart disease. Int J Technol Assess Health Care 2003; 19:476-89
55. Drummond M, Sculpher M, Torrance G., et al. Methods for the economic evaluation of health care programmes. 3 edition. Oxford University Press; New York: 2005
56. Gray A, Clarke P, Wolstenholme J., et al. Applied Methods of Cost-effectiveness Analysis in Healthcare. Oxford University Press, New York; 2011
57. Annema C, Luttik ML, Jaarsma T. Do Patients With Heart Failure Need a Case Manager? J Cardiovasc Nurs 2009; 24: 127-31
58. Husereau D, Drummond M, Petrou S., et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med 2013; 11:80
59. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Available from: www.bmj.com/content/346/bmj.f1049
60. TEAM-HF. Available from: www.team-hf.com
61. Boutron I, Moher D, Altman D.G., et al. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008; 148:295-309
62. Krumholz H, Currie P, Riegel B., et al. A taxonomy for disease management: a scientific statement from the american heart association disease management taxonomy writing group. Circulation 2006; 114:1432-45